Eliminates healthy tissue damage and maximizes tumor ablation via photodynamic gel.

This technology is an injectable gel combining ethanol, a polymer, and a light-activated photosensitizer to locally destroy tumors, enhance treatment precision, and enable real-time imaging for safer and more effective cancer therapy.

Background

Localized cancer therapies are crucial for treating tumors directly at their source without subjecting the body to harsh systemic drugs. One common method is percutaneous ethanol injection, which involves delivering pure alcohol directly into a lesion to destroy cancerous cells. This approach is highly valued in clinical settings because it is inexpensive, straightforward, and minimally invasive compared to traditional surgery. Because of its widespread accessibility, there is a pressing clinical need to optimize this therapy so patients can receive effective, affordable cancer care without compromising safety.

Despite these advantages, current ethanol injection treatments suffer from critical limitations that hinder their success. A primary issue is the unpredictable distribution of the liquid once it enters the body. Because tumors are often dense and structurally irregular, the injected alcohol frequently fails to spread evenly, leaving malignant cells untreated. Furthermore, because the liquid flows freely, there is a high risk of leakage outside the targeted area. When this destructive fluid escapes the tumor boundaries, it causes collateral damage to surrounding healthy tissues. Finally, the diverse biological nature of tumors often creates natural resistance to the alcohol, severely reducing the overall efficacy of the procedure.

Technology

This novel cancer therapy uses an injectable mixture of anhydrous ethanol, ethyl cellulose polymer, and a light-sensitive benzoporphyrin derivative. Upon contact with the watery environment of biological tissue, the fluid instantly transforms into a localized gel. This gel securely traps the ethanol within the targeted tumor, killing cancer cells through severe dehydration and coagulation. Additionally, the light-sensitive agent serves a dual purpose. When exposed to near-infrared light, it produces reactive oxygen species that further destroy tumor tissue. It also emits a fluorescent glow, allowing medical professionals to visually guide the delivery process and monitor treatment in real time.

This technology stands out by solving the major limitations of standard ethanol injections, which frequently leak and damage surrounding healthy tissue. By gelling in place, the formulation dramatically improves local retention and patient safety. Furthermore, it is uniquely differentiated as the first treatment to combine ethanol ablation, a polymer, and photodynamic therapy into a single direct injection. Existing alternatives are either restricted to intravenous use or lack cancer-specific applications. By synergizing physical ablation with light-activated destruction and real-time imaging, this multi-agent approach significantly enhances targeted tumor coverage and overall efficacy compared to traditional single-method therapies.

Benefits

  • Delivers superior anti-tumor efficacy by synergistically combining localized ethanol ablation with light-activated photodynamic therapy.
  • Improves patient safety by forming a gel upon injection, which retains the ethanol within the target area and minimizes harmful leakage into surrounding healthy tissue.
  • Enables real-time, image-guided delivery and treatment monitoring through the fluorescent properties of the integrated photosensitizer.
  • Significantly increases the distribution volume and therapeutic coverage within the targeted tumor or precancerous lesion.
  • Offers a highly customizable formulation, allowing clinicians to adjust polymer and photosensitizer concentrations to achieve the desired fluidity and potency.

Applications

  • Localized solid tumor ablation
  • Image-guided intratumoral cancer treatment
  • Photodynamic precancerous lesion therapy
  • Fluorescence-guided tumor surgery monitoring
  • Enhanced percutaneous ethanol injection

Additional info

This injectable formulation integrates anhydrous ethanol, ethyl cellulose, and a benzoporphyrin derivative for localized cancer therapy. The polymer forms an in-situ gel upon contact with aqueous tissue, sequestering ethanol to induce necrotic coagulation while minimizing leakage. Simultaneously, the photosensitizer enables near-infrared light-activated photodynamic therapy, generating cytotoxic reactive oxygen species. This synergistic approach provides dual-mode tumor ablation and fluorescence-guided monitoring, improving delivery precision and therapeutic outcomes.